CSL Limited, Alkermes
David W. Anstice is a retired senior executive and company director, working globally, and based in Pennsylvania, USA. He retired as a senior executive of Merck & Co., Inc., a world leader in the discovery, development, manufacture and marketing of prescription medicines and vaccines, in September 2008 after a 35 year career at the Company. He had reported to Merck's CEO in various assignments, including President, The Americas; President, Asia Pacific; and President, Japan, since 1994. Prior to that date he was President of Merck's European business. He served on Merck's Executive Committee, the Company's senior management team, commencing in 1990, and served as the Merck representative to the Biotechnology Industry Organization in Washington, D.C., for 10 years.
Today, he is a non-executive Director of two public companies, CSL Limited, based in Melbourne, Australia (ASX), and Alkermes Plc, based in Dublin, Ireland (NASDAQ).
David is also Chairman and President of the University of Sydney USA Foundation, was awarded an Honorary Fellowship of the University of Sydney in 2007, is a member of the Board of the United States Studies Centre at the University of Sydney, and is a Member of the United States Advisory Council of the American Australian Association in New York. He is a member of the Board of the US Foundation of the University of the Valley of Guatemala. In addition to being an Adjunct Professor at the University of Sydney Business School, he is also a member of the School's Board of Advice.
Born in Wagga Wagga, and an Economics graduate of the University of Sydney in Australia, David joined Merck in 1974, in Australia. He progressed through a series of positions, and on several continents, including Managing Director, Merck Sharp & Dohme Australia; Vice President, International Human Health Marketing, Merck Sharp & Dohme International; President, U.S. Human Health; President, Human Health Europe; President, Human Health, The Americas; from 2000 until July 2006, he was responsible for Merck's joint ventures with Schering-Plough, and from January 2002 to July 2005 he was responsible for Merck's human health businesses in Canada, Latin America, Japan, Australia and New Zealand, and until September 2006, David was President, Asia Pacific Human Health, responsible for Japan, China, Australia, Korea, and other Asia Pacific country human health pharmaceutical business of Merck & Co., Inc. During 2007, he acted as President, Global Human Health and President, Banyu Pharmaceuticals, responsible for all Merck's business in Japan, on short term assignments.
He served as Chairman of the National Pharmaceutical Council, Reston, Virginia in 1997, and represented Merck on the Board of Directors, Biotechnology Industry Organization in Washington, D.C. from 1996 to 2005.